Recro Pharma, Inc. (REPH)
(Delayed Data from NSDQ)
$9.00 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.00 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
by Zacks Equity Research
Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
5 Domestic Stocks to Gain From Thaw in Trade Talks
by Zacks Equity Research
The United States and China's outstanding disagreements on a few key issues could delay a favorable deal.
Recro Pharma (REPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recro Pharma (REPH) delivered earnings and revenue surprises of 4.48% and 9.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
FDA Sets Action Date for Recro's Pain Management Candidate
by Zacks Equity Research
The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.
Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recro Pharma (REPH) delivered earnings and revenue surprises of 54.07% and 29.35%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
by Zacks Equity Research
Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.
Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View
by Zacks Equity Research
Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.
Company News for November 29, 2016
by Zacks Equity Research
Companies in the News are: CTSH,PZRX,REPH,SFUN